Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Lilly Wades Through The Patent Cliff, It Sees Hope In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

Citi Investment Research says Lilly is the “best positioned” among U.S. pharma in China; here’s why.

Advertisement

Related Content

Sanofi China GM Fabrice Baschiera On Winning The Insulin Battle In China: An Interview With PharmAsia News (Part 2 of 2)
Chinese Health Authorities, Alarmed By Prospect Of 100 Million-plus Diabetics, Create Doctor Training Programs As Global Drug Outfits Step Up R&D

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC076940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel